FocalTherics (NASDAQ:FOCL) SVP Acquires $23,750.00 in Stock

FocalTherics (NASDAQ:FOCL) SVP Steven Annen bought 5,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the completion of the transaction, the senior vice president directly owned 136,490 shares of the company’s stock, valued at $648,327.50. This represents a 3.80% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

FocalTherics Stock Performance

NASDAQ:FOCL opened at $4.36 on Thursday. The firm’s 50-day moving average is $5.37. FocalTherics has a 52-week low of $1.30 and a 52-week high of $6.40. The company has a quick ratio of 0.99, a current ratio of 1.60 and a debt-to-equity ratio of 1.79. The company has a market capitalization of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The company had revenue of $13.20 million during the quarter. Equities analysts forecast that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on FOCL. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $7.75.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FOCL. Flax Pond Capital LLC purchased a new position in shares of FocalTherics in the fourth quarter worth $2,623,000. Leonteq Securities AG bought a new position in shares of FocalTherics during the fourth quarter worth $313,000. Rock Springs Capital Management LP grew its stake in FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 91,500 shares in the last quarter. Kovack Advisors Inc. bought a new stake in FocalTherics in the 4th quarter valued at $53,000. Finally, Lido Advisors LLC bought a new stake in FocalTherics in the 1st quarter valued at $40,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.